Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
NCT02082522
Terminated
Photodynamic therapy (PDT) is a combination of a drug, porfimer sodium (Photofrin), which is activated by a light from a laser that emits no heat. This technique works to allow the medical doctor to specifically target and destroy abnormal or cancer cells while limiting damage to surrounding healthy tissue. The activation of the drug is done by lighting the abnormal areas using a fiber optic device (very fine fiber like a fishing line that permits light transmission) inserted into a flexible tub... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2019
Locations: Western Regional Medical Center, Inc., Goodyear, Arizona +30 locations
Conditions: Hilar Cholangiocarcinoma
Register for Updates
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
NCT00262821
Terminated
This randomized phase III trial is studying cisplatin, radiation therapy, and tirapazamine to see how well they work compared to cisplatin and radiation therapy in treating patients with cervical cancer. Drugs used in chemotherapy, such as cisplatin and tirapazamine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Internal radiation uses radioactive material pla... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/19/2019
Locations: University of Alabama at Birmingham, Birmingham, Alabama +281 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Register for Updates
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
NCT01055496
Completed
This is a phase 1 trial designed to evaluate safety and tolerability of chemotherapy in combination with inotuzumab ozogamicin, an investigational product, in adults with CD22-positive non-Hodgkin's lymphoma. The trial will involve two arms. In one arm, subjects will receive chemotherapy regimen R-CVP (rituximab, cyclophosphamide, vincristine and prednisone). In the other arm, subjects will receive R-GDP (rituximab, gemcitabine, cisplatinum and dexamethasone). Subjects in both arms will also rec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2019
Locations: Davis Cancer Pavillion and Shands Medical Plaza, Gainesville, Florida +27 locations
Conditions: Lymphoma, B-Cell
Register for Updates
Nintedanib (BIBF 1120) in Mesothelioma
NCT01907100
Terminated
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2019
Locations: University of Alabama at Birmingham, Birmingham, Alabama +122 locations
Conditions: Mesothelioma
Register for Updates
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
NCT00603915
Completed
Cisplatin or Carboplatin will be given on day 1 every 21 days for 6 cycles; Gemcitabine will be given on day 1 and day 8 every 21 days for 6 cycles. Those patients that do not progress on GC after 6 cycles of chemotherapy will be started on erlotinib daily until disease progression. A cycle of erlotinib will be 28 days. Patients who progress on GC will be offered erlotinib as well,in order to evaluate its activity as a single-agent in the second-line setting. Patients previously treated with GC... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2019
Locations: Princess Margaret Hospital, Toronto, Ontario
Conditions: Nasopharyngeal Cancer
Register for Updates
Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
NCT01083537
Terminated
The best way to treat MBO in patients with ovarian cancer has not been studied enough by trials that assess how more than one treatment arm (surgical, chemotherapeutic, supportive care approaches) affects clinical outcomes like resolution of bowel obstruction, survival, and quality of life. To improve patient outcomes, we must assess which patients will do better with palliative surgery, chemotherapy, or best supportive care. This study will gather safety information, and how reasonable it is to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2019
Locations: Princess Margaret Hospital, Toronto, Ontario
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Bowel Obstruction
Register for Updates
Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery
NCT00331760
Completed
RATIONALE: Specialized radiation therapy (RT), such as intensity-modulated radiation therapy (IMRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving intensity-modulated radiation therapy to the pelvis with or without chemotherapy after surgery ma... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/01/2019
Locations: Auburn Radiation Oncology, Auburn, California +152 locations
Conditions: Cervical Cancer, Endometrial Cancer
Register for Updates
Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00030576
Completed
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with cisplatin may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining erlotinib and cisplatin in treating patients who have recurrent or metastatic head and neck cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/09/2018
Locations: Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario +5 locations
Conditions: Head and Neck Cancer
Register for Updates
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
NCT00085098
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy alone is as effective as chemotherapy plus radiation therapy in treating germ cell tumor. PURPOSE: This randomized phase III trial is studying radiation therapy alone to see how well it works compared to chemotherapy and radiation therapy in treating patients with... Read More
Gender:
ALL
Ages:
Between 3 years and 25 years
Trial Updated:
08/08/2018
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +106 locations
Conditions: Brain Tumor, Central Nervous System Tumor
Register for Updates
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
NCT00045162
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin combined with irinotecan is more effective than cisplatin combined with etoposide in treating extensive-stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with either irinotecan or etoposide in treating patients who hav... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/03/2018
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +407 locations
Conditions: Lung Cancer
Register for Updates
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
NCT00949650
Completed
This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2018
Locations: Highlands Oncology Group, Fayetteville, Arkansas +132 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
Register for Updates
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
NCT00369122
Completed
This phase II trial is studying how well giving bevacizumab together with radiation therapy and cisplatin works in treating patients with previously untreated locally advanced cervical cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of cervical cancer by blocking blood flo... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
02/21/2018
Locations: Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California +105 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7
Register for Updates